TDOC Stock Overview
Teladoc Health, Inc. provides virtual healthcare services on a business-to-business basis in the United States and internationally.
Teladoc Health Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$72.03|
|52 Week High||US$308.00|
|52 Week Low||US$66.93|
|1 Month Change||-24.25%|
|3 Month Change||-48.04%|
|1 Year Change||-74.84%|
|3 Year Change||18.55%|
|5 Year Change||260.15%|
|Change since IPO||152.74%|
Recent News & Updates
Teladoc: A Healthcare Stock Worth Considering Today
Teladoc shares recently broke a new 52-week low and are down 74% in the past year. Teladoc's decline in share price is part of a larger downward trend in high growth tech companies as a result of rising interest rates and inflation. The global telehealth market is forecasted to reach over $500 billion by 2028, leaving Teladoc well-positioned given its status as a pioneer in the virtual medicine space. As competition continues to heat up, Teladoc will have to fend off newcomers, traditional healthcare companies, and even tech giants like Amazon.
What Does Competition From Amazon Care Mean To Teladoc?
As Amazon Care continues to expand its virtual healthcare offerings, it will offer a similar range of services to Teladoc, as well as providing in-person care and prescription delivery services. Amazon Care is indeed taking the virtual healthcare market by storm, with its considerable cash and equivalents of $29.9B, compared to $823.8M for TDOC. As competition heats up, consensus estimates suggest that there is enough room in the personalized healthcare market for multiple major players moving forward. We discuss whether investors should add TDOC stock now.
Prevalent Insider Selling Confirms the Teladoc Health's (NYSE:TDOC) Decline
It is often said that the market takes a staircase up and an elevator down, but in some cases, stocks can take an elevator both ways. Such was the case with Teladoc Health. Over the last 2 years, it rose over 250% just to give back all the gains and return to the starting line.
|TDOC||US Healthcare Services||US Market|
Return vs Industry: TDOC underperformed the US Healthcare Services industry which returned -35.5% over the past year.
Return vs Market: TDOC underperformed the US Market which returned 4.2% over the past year.
|TDOC Average Weekly Movement||8.8%|
|Healthcare Services Industry Average Movement||10.0%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||15.4%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: TDOC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: TDOC's weekly volatility (9%) has been stable over the past year.
About the Company
Teladoc Health, Inc. provides virtual healthcare services on a business-to-business basis in the United States and internationally. It covers various clinical conditions, including non-critical, episodic care, chronic, and complicated cases like cancer and congestive heart failure, as well as offers telehealth solutions, chronic condition management, expert medical services, behavioral health solutions, guidance and support, and platform and program services. It serves health employers, health plans, hospitals, health systems, and insurance and financial services companies.
Teladoc Health Fundamentals Summary
|TDOC fundamental statistics|
Is TDOC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TDOC income statement (TTM)|
|Cost of Revenue||US$598.22m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-5.07|
|Net Profit Margin||-43.60%|
How did TDOC perform over the long term?See historical performance and comparison
Is Teladoc Health undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: TDOC ($72.03) is trading below our estimate of fair value ($229.85)
Significantly Below Fair Value: TDOC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: TDOC is unprofitable, so we can't compare its PE Ratio to the US Healthcare Services industry average.
PE vs Market: TDOC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TDOC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TDOC is good value based on its PB Ratio (0.7x) compared to the US Healthcare Services industry average (3.4x).
How is Teladoc Health forecast to perform in the next 1 to 3 years based on estimates from 22 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TDOC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TDOC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TDOC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TDOC's revenue (21.4% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: TDOC's revenue (21.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TDOC's Return on Equity is forecast to be low in 3 years time (2.4%).
How has Teladoc Health performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TDOC is currently unprofitable.
Growing Profit Margin: TDOC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TDOC is unprofitable, and losses have increased over the past 5 years at a rate of 52.6% per year.
Accelerating Growth: Unable to compare TDOC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TDOC is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (16.1%).
Return on Equity
High ROE: TDOC has a negative Return on Equity (-5.08%), as it is currently unprofitable.
How is Teladoc Health's financial position?
Financial Position Analysis
Short Term Liabilities: TDOC's short term assets ($1.2B) exceed its short term liabilities ($302.1M).
Long Term Liabilities: TDOC's short term assets ($1.2B) do not cover its long term liabilities ($1.4B).
Debt to Equity History and Analysis
Debt Level: TDOC's net debt to equity ratio (2.5%) is considered satisfactory.
Reducing Debt: TDOC's debt to equity ratio has reduced from 18.4% to 7.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TDOC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if TDOC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Teladoc Health current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TDOC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TDOC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TDOC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TDOC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TDOC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jason Gorevic (49 yo)
Mr. Jason Nathanial Gorevic has been Chief Executive Officer at Teladoc Health, Inc. (formerly known as Teladoc, Inc.) (Formerly TelaDoc Medical Services Inc.) since June 2009. Mr. Gorevic served as Direct...
CEO Compensation Analysis
Compensation vs Market: Jason's total compensation ($USD8.46M) is about average for companies of similar size in the US market ($USD11.47M).
Compensation vs Earnings: Jason's compensation has increased whilst the company is unprofitable.
Experienced Management: TDOC's management team is seasoned and experienced (6.9 years average tenure).
Experienced Board: TDOC's board of directors are considered experienced (5.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TDOC insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.4%.
Teladoc Health, Inc.'s employee growth, exchange listings and data sources
- Name: Teladoc Health, Inc.
- Ticker: TDOC
- Exchange: NYSE
- Founded: 2002
- Industry: Health Care Technology
- Sector: Healthcare
- Implied Market Cap: US$11.531b
- Shares outstanding: 160.09m
- Website: https://www.teladochealth.com
Number of Employees
- Teladoc Health, Inc.
- 2 Manhattanville Road
- Suite 203
- New York
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/26 01:04|
|End of Day Share Price||2022/01/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.